Equities research analysts at Janney Montgomery Scott initiated coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a report issued on Wednesday, The Fly reports. The firm set a “buy” rating on the biotechnology company’s stock.

Several other brokerages also recently weighed in on SRPT. HC Wainwright set a $75.00 target price on shares of Sarepta Therapeutics and gave the company a “buy” rating in a research note on Wednesday. Oppenheimer reissued a “buy” rating and issued a $76.00 target price on shares of Sarepta Therapeutics in a research note on Wednesday, December 27th. UBS Group reissued an “outperform” rating and issued a $56.51 target price (down previously from $76.00) on shares of Sarepta Therapeutics in a research note on Wednesday, December 27th. BidaskClub raised shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, December 25th. Finally, Zacks Investment Research downgraded shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 15th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and nineteen have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $63.79.

Sarepta Therapeutics (NASDAQ:SRPT) traded up $0.30 during trading on Wednesday, hitting $58.55. 1,660,000 shares of the company traded hands, compared to its average volume of 1,440,000. Sarepta Therapeutics has a 1-year low of $26.26 and a 1-year high of $59.00. The company has a quick ratio of 9.52, a current ratio of 10.44 and a debt-to-equity ratio of 0.04. The stock has a market cap of $3,780.00, a price-to-earnings ratio of -28.70 and a beta of 1.37.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Wednesday, October 25th. The biotechnology company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.86) by $0.66. Sarepta Therapeutics had a negative net margin of 112.08% and a negative return on equity of 51.72%. The firm had revenue of $45.95 million during the quarter, compared to the consensus estimate of $41.29 million. During the same quarter in the previous year, the company posted ($0.95) EPS. research analysts forecast that Sarepta Therapeutics will post -3.11 earnings per share for the current fiscal year.

In related news, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of the stock in a transaction that occurred on Thursday, November 30th. The shares were sold at an average price of $55.89, for a total transaction of $372,618.63. Following the completion of the sale, the director now owns 13,333 shares of the company’s stock, valued at approximately $745,181.37. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Shamim Ruff sold 10,000 shares of the stock in a transaction that occurred on Monday, November 6th. The stock was sold at an average price of $55.00, for a total transaction of $550,000.00. Following the sale, the senior vice president now directly owns 37,045 shares of the company’s stock, valued at approximately $2,037,475. The disclosure for this sale can be found here. Corporate insiders own 9.60% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. increased its position in Sarepta Therapeutics by 4.0% during the 2nd quarter. Vanguard Group Inc. now owns 4,259,029 shares of the biotechnology company’s stock worth $143,572,000 after purchasing an additional 162,543 shares in the last quarter. HealthCor Management L.P. increased its position in Sarepta Therapeutics by 31.1% during the 2nd quarter. HealthCor Management L.P. now owns 2,031,890 shares of the biotechnology company’s stock worth $68,495,000 after purchasing an additional 481,890 shares in the last quarter. Jennison Associates LLC increased its position in Sarepta Therapeutics by 103.9% during the 3rd quarter. Jennison Associates LLC now owns 1,143,853 shares of the biotechnology company’s stock worth $51,885,000 after purchasing an additional 582,894 shares in the last quarter. Eagle Asset Management Inc. increased its position in Sarepta Therapeutics by 26.0% during the 3rd quarter. Eagle Asset Management Inc. now owns 1,006,222 shares of the biotechnology company’s stock worth $49,858,000 after purchasing an additional 207,810 shares in the last quarter. Finally, Emerald Advisers Inc. PA increased its position in Sarepta Therapeutics by 2.1% during the 3rd quarter. Emerald Advisers Inc. PA now owns 893,484 shares of the biotechnology company’s stock worth $40,528,000 after purchasing an additional 18,077 shares in the last quarter. 82.02% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of United States and international copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/03/sarepta-therapeutics-srpt-research-coverage-started-at-janney-montgomery-scott.html.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

The Fly

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.